Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System-Reference-Cited by-同舟云学术

Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System

Published:2023-02-27 Issue:1 Volume:2 Page:
ISSN:2769-2558
Container-title:Psychiatry and Clinical Neurosciences Reports
language:en
Short-container-title:PCN Reports

Author:

Yokoi Yuma¹²^ORCID,Kashiwagi Hiroko³^ORCID,Funada Daisuke³^ORCID,Yamashita Shingo²,Kubota Chika²^ORCID

Affiliation:

1. Department of Educational Promotion, Clinical Research & Education Promotion Division, National Center Hospital National Center of Neurology and Psychiatry Tokyo Japan

2. Department of Psychiatry, National Center Hospital National Center of Neurology and Psychiatry Tokyo Japan

3. Department of Forensic Psychiatry, National Center Hospital National Center of Neurology and Psychiatry Tokyo Japan

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pcn5.79

Reference10 articles.

1. Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies

2. Narboux‐NêmeN SagnéC DolyS DiazSL MartinCBP AngenardG et al.Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences.Neuropsychopharmacology.2011;36(12):2538–50.

3. XENAZINE (tetrabenazine) tablets for oral use. Prescribing information. Lundbeck; September 2017. Accessed February 21 2023.https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021894s013lbl.pdf

4. OpenVigil FDA – Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications

5. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports